|Bid||520.16 x 1000|
|Ask||526.00 x 800|
|Day's Range||519.97 - 530.07|
|52 Week Range||441.00 - 664.64|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||14.96|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||628.36|
The U.S. Food and Drug Administration granted Regeneron Pharmaceuticals' (NASDAQ: REGN) antibody treatment for the coronavirus authorization late last year. Regeneron reported $262 million in sales of REGEN-COV in the first quarter. Regeneron shares have increased about 5% year to date.
REGN vs. INCY: Which Stock Is the Better Value Option?
Is (REGN) Outperforming Other Medical Stocks This Year?